Inclusion Criteria:

Age Eligible for Study: 18 years - NA, Genders Eligible for Study: Both

Criteria

Inclusion criteria:

- HIV infection

- T CD4 count cell level above 200 per mm3

- Serology Hepatitis B negative (AgHBs, AbHBs and AbHBc negative)

- unchanged ARV for the last 3 months for patients who are receiving ARV at the
screening visit

- Undetectable for the last 6 months with ARV for any patient with T CD4 level below
350 per mm3

- Pregnancy test negative at the screening and inclusion visits

Exclusion Criteria:

- Any injection of the vaccine against Hepatitis B in the medical history

- Acute cytolysis in the last 3 months with transaminases equal or above 5 times the
upper normal range for HIV-HCV coinfected patients, or transaminases equal or above 2
times the upper normal for non coinfected patients

- Any vaccine received one month before the inclusion

- History of intolerance to any component of GenHevac-B

- Evolutive opportunistic infection treated the month before the screening visit

- Severe and acute pyretic infection or unexplained fever the week before inclusion

- Evolutive hemopathy or solid-organ cancer

- Prothrombin factor equal or below 50 percent and/or platelets equal or below 50 000
per mm3

- Immunosuppressive treatment or general corticotherapy (equal or above 0,5 mg per kg
per day during above 7 days) in the last 6 months before the screening visit

- Immunomodulating treatment (interferon, interleukin-2,etc) or plan in the next 6
months

- Splenectomy

- Decompensated cirrhosis (Child Pugh B or C)

- Kidney deficient function (creatinine clearance below 50 ml per mn)

- Other immunocompromised condition not related to HIV infection (solid-organ
transplantation, chemotherapy in the last 6 months)

- Any participation to another clinical trial plan until Week 28